Ariad proposes follow-on

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) said late Wednesday that it is planning a follow-on underwritten by JPMorgan; Cowen; and Jefferies. Last month, FDA granted accelerated approval to Ariad's Icl...